Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01659385 · ClinicalTrials.gov registry record
Leptin Levels in Papillary Thyroid Cancer
A clinical trial, sponsored by University of Nebraska.
- Completed
- Registry status
- 18
- Enrollment target
NCT01659385: Completed study, sponsored by University of Nebraska.
NCT01659385 is a clinical trial that has completed, run by University of Nebraska. The registered enrollment target is 18 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01659385 has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate Leptin levels in females, in the setting of papillary thyroid cancer, benign thyroid nodules, and in normal females without thyroid disease.
Primary Outcome
Assessing serum leptin levels in females with treated papillary thyroid carcinoma and compared to females with proven benign thyroid nodules and females with normal thyroid glands. All groups were matched by gender, age, and BMI to limit confounders.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-08-07 |
| Est. Completion | 2013-04-25 |
What the finished NCT01659385 record still lists
NCT01659385 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 18 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01659385 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01659385 about?
NCT01659385 is a clinical study titled "Leptin Levels in Papillary Thyroid Cancer". The purpose of this study is to evaluate Leptin levels in females, in the setting of papillary thyroid cancer, benign thyroid nodules, and in normal females without thyroid disease.
What is the current status of trial NCT01659385?
This trial is currently completed. The enrollment target is 18 participants. The study started on 2012-08-07. Estimated completion is 2013-04-25.
Who is sponsoring clinical trial NCT01659385?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI